Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients

被引：0
|
作者：
Shen, B. [1 ,2 ]
Pan, B. [1 ,2 ]
Wu, Y. [1 ,2 ]
Shi, L. [1 ,2 ]
Gao, J. [1 ,2 ]
Du, X. [1 ,2 ]
Feng, J. [1 ,2 ]
机构：
[1] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Peoples R China
[2] Jiangsu Canc Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Elderly NSCLC; Tislelizumab; First-line;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-03
引用
收藏
页码：S317 / S318
页数：2
相关论文
共 50 条
  • [21] Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma
    Yoon, Harry H.
    Kato, Ken
    Hubner, Richard
    Raymond, Eric
    Tao, Aiyang
    Liu, Sumei
    Qazi, Ibrahim
    Xu, Jian-Ming
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [22] Anti-EGFR Monoclonal Antibodies plus Chemotherapy in the First-Line Treatment of Advanced NSCLC: A Meta-Analysis
    Stock, Gustavo
    Aguiar, Pedro, Jr.
    Santoro, Ilka
    Tadokoro, Hakaru
    De Mello, Ramon
    Lopes, Gilberto
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S333 - S334
  • [23] Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Cui, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S3 - S3
  • [24] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
    Chen, Pingyu
    Wang, Xintian
    Zhu, Shengwen
    Li, Hongchao
    Rui, Mingjun
    Wang, Yingcheng
    Sun, Haikui
    Ma, Aixia
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [25] Optimizing first-line treatment options for patients with advanced NSCLC
    Wakelee, H
    Belani, CP
    [J]. ONCOLOGIST, 2005, 10 : 1 - 10
  • [26] First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Jotte, Robert M.
    Socinski, Mark A.
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    West, Howard J.
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Cappuzzo, Federico
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S302 - S303
  • [27] First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Cappuzzo, Frederico
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    Jotte, Robert
    West, Howard
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Socinski, Mark
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1296 - S1297
  • [28] Cost-effectiveness analysis of sintilimab plus chemotherapy versus camrelizumab plus chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China
    Rui, Mingjun
    Fei, Zhengyang
    Wang, Yingcheng
    Zhang, Xueke
    Ma, Aixia
    Sun, Haikui
    Li, Hongchao
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 618 - 629
  • [29] Bevacizumab plus chemotherapy extends survival of patients with first-line nonsquamous NSCLC
    不详
    [J]. ONCOLOGY-NEW YORK, 2005, 19 (04): : 473 - 473
  • [30] Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)
    Chuang, Chienhuai
    Liu, Tsung-Hao
    Hsu, Meng-Chi
    Chang, Mo-Jung
    Cheng, Ann-Lii
    Hsu, Chiun
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1398 - S1398
12345